Guess we are going to have to disagree on this one...I think there is a very good chance the company will go it alone...(Please..I am not saying it is a certainty)...I know I would....
Amarin is closer to Coke than you might think..IMO Amarin will make a very poor generic..Being the expert you claim to be, you of course understand that most generics' strategy is simply to under cut the Price of the Brand Drug..That is profitable in most drugs because the Brand Companies charge high premiums to counter the effect of the very expensive FDA Marketing Process...This is not going to be the case in Amarin...Amarin can make a fortune in sales without marking the drug up because of the tremendous volume...JT likes to say..V is not a price drug...It's a volume drug...And this not just speculation on my part...JT has repeated that over and over...To compete with Amarin the generics are going to need suppliers and processors and they are going to have to wait in line behind Amarin who will have over 6 years to tie up these vital companies...It is in violation of every rule of commerce that the generics are going to be able to produce the drug at a lower price than Amarin..
":>)
So undercutting Amarin's drug price is going to be quite a trick..If you know how they (the generics) are going to do that...I'm sure the generics would like to know...
By the time Generics get market ready..Amarin will be selling millions and millions of capsules and even at razor thin markets they will be making mind bending amounts of money...
Good luck to the generics...Bold Prediction...No Generic Company will decide to pursue Amarin's drug Vascepa...just too many obstacles
Market Data 
Markets 
AI
